Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of ATI-7505 in postprandial distress syndrome
2007-005008-41Phase 2Terminated
- Sponsor
- Procter & Gamble
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of naronapride in Postprandial Distress Syndrome (PDS) and functional dyspepsia (FD) (4 arms), sponsored by Procter & Gamble. Started Feb 2008; status: terminated.
02
Drugs
naronapride
03
Conditions
Postprandial Distress Syndrome (PDS)functional dyspepsia (FD)
Beyond the preview
Go deeper on 2007-005008-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005008-41.